139 related articles for article (PubMed ID: 3828996)
21. Macrophages as effector cells of protective immunity in murine schistosomiasis. V. Variation in macrophage schistosomulacidal and tumoricidal activities among mouse strains and correlation with resistance to reinfection.
James SL; Skamene E; Meltzer MS
J Immunol; 1983 Aug; 131(2):948-53. PubMed ID: 6863937
[TBL] [Abstract][Full Text] [Related]
22. Quantification of the strength of cell-cell adhesion: the capture of tumor cells by activated murine macrophages proceeds through two distinct stages.
Somers SD; Whisnant CC; Adams DO
J Immunol; 1986 Feb; 136(4):1490-6. PubMed ID: 3080524
[TBL] [Abstract][Full Text] [Related]
23. Role of the thymus in control of autoreactivity or allotolerance in syngeneic and allogeneic bone marrow chimeras treated with bacterial adjuvants.
Taniguchi K; Gondo H; Nomoto K
J Immunol; 1984 Oct; 133(4):1735-9. PubMed ID: 6088626
[TBL] [Abstract][Full Text] [Related]
24. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
Yoshida R; Yoneda Y; Kuriyama M; Kubota T
J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
[TBL] [Abstract][Full Text] [Related]
25. Imbalanced accumulation of ribosomal RNA in macrophages activated in vivo or in vitro to a cytolytic stage.
Varesio L
J Immunol; 1985 Feb; 134(2):1262-7. PubMed ID: 3965571
[TBL] [Abstract][Full Text] [Related]
26. Effector mechanisms of cytolytically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors.
Adams DO
J Immunol; 1980 Jan; 124(1):286-92. PubMed ID: 6985641
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture.
Bartholeyns J; Lombard Y; Poindron P
Anticancer Res; 1988; 8(1):145-51. PubMed ID: 3358630
[TBL] [Abstract][Full Text] [Related]
28. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
29. Effects of bacillus of Calmette-Guerin, Candida albicans and human recombinant interferon-gamma on RNA metabolism and on in vitro release of tumor necrosis factor-alpha by human monocytes/macrophages.
Busolo F; Conventi L; Grigolon M; Bassi P; Milani C; Meneghini A; Pagano F
New Microbiol; 1993 Jul; 16(3):259-66. PubMed ID: 7690109
[TBL] [Abstract][Full Text] [Related]
30. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
31. Macrophage-mediated lysis of a beta-cell line, tumour necrosis factor-alpha release from bacillus Calmette-Guérin (BCG)-activated murine macrophages and interleukin-8 release from human monocytes are dependent on extracellular glutamine concentration and glutamine metabolism.
Murphy C; Newsholme P
Clin Sci (Lond); 1999 Jan; 96(1):89-97. PubMed ID: 9857111
[TBL] [Abstract][Full Text] [Related]
32. A role for the macrophage in in vivo and in vitro resistance to murine bladder tumor cell growth.
Droller MJ; Remington JS
Cancer Res; 1975 Jan; 35(1):49-53. PubMed ID: 1109796
[TBL] [Abstract][Full Text] [Related]
33. Negative and positive immunobiological responses in mice pretreated with Bacillus Calmette-Guérin cell wall.
Mizushima Y; Wepsic HT; Yamamura Y; DeSilva MA; Janns G; Larson CH
Cancer Res; 1984 Jan; 44(1):20-4. PubMed ID: 6228292
[TBL] [Abstract][Full Text] [Related]
34. Predisposition of [125I]5-iodo-2'-deoxyuridine-labeled normal and neoplastic mouse fibroblasts to lysis by normal macrophages.
Evans R; Eidlen DM
J Natl Cancer Inst; 1983 Nov; 71(5):983-9. PubMed ID: 6580500
[TBL] [Abstract][Full Text] [Related]
35. Newcastle disease virus activates macrophages for anti-tumor activity.
Schirrmacher V; Bai L; Umansky V; Yu L; Xing Y; Qian Z
Int J Oncol; 2000 Feb; 16(2):363-73. PubMed ID: 10639582
[TBL] [Abstract][Full Text] [Related]
36. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
[TBL] [Abstract][Full Text] [Related]
37. Effect of poly I:C-activated peritoneal cells on the take of transplantable murine tumours.
Minárovits J; Karczag E; Földes I
Acta Microbiol Hung; 1987; 34(3-4):197-205. PubMed ID: 3129897
[TBL] [Abstract][Full Text] [Related]
38. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
Brunda MJ; Taramelli D; Holden HT; Varesio L
J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
[TBL] [Abstract][Full Text] [Related]
39. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
Schorlemmer HU; Bosslet K; Sedlacek HH
Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
[TBL] [Abstract][Full Text] [Related]
40. Chemotaxis of resident, elicited and immunologically activated murine peritoneal macrophages.
Staer AF; Rhodes JM; Bennedsen J; Olesen Larsen S
Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):117-21. PubMed ID: 6880746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
